Tempest Therapeutics Statistics
Total Valuation
TPST has a market cap or net worth of $25.77 million. The enterprise value is $14.13 million.
Important Dates
The next estimated earnings date is Friday, November 15, 2024, after market close.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TPST has 26.57 million shares outstanding. The number of shares has increased by 42.10% in one year.
| Current Share Class | 26.57M |
| Shares Outstanding | 26.57M |
| Shares Change (YoY) | +42.10% |
| Shares Change (QoQ) | +1.40% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 10.54% |
| Float | 22.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.36 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.17, with a Debt / Equity ratio of 1.20.
| Current Ratio | 2.17 |
| Quick Ratio | 2.14 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.25 |
Financial Efficiency
Return on equity (ROE) is -289.26% and return on invested capital (ROIC) is -62.14%.
| Return on Equity (ROE) | -289.26% |
| Return on Assets (ROA) | -54.28% |
| Return on Capital (ROIC) | -62.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.87M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.64% in the last 52 weeks. The beta is -2.78, so TPST's price volatility has been lower than the market average.
| Beta (5Y) | -2.78 |
| 52-Week Price Change | -73.64% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 2.59 |
| Relative Strength Index (RSI) | 37.76 |
| Average Volume (20 Days) | 8,411,336 |
Short Selling Information
The latest short interest is 3.72 million, so 14.00% of the outstanding shares have been sold short.
| Short Interest | 3.72M |
| Short Previous Month | 1.86M |
| Short % of Shares Out | 14.00% |
| Short % of Float | 16.27% |
| Short Ratio (days to cover) | 1.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -31.66M |
| Pretax Income | -31.75M |
| Net Income | -31.75M |
| EBITDA | -31.25M |
| EBIT | -31.66M |
| Earnings Per Share (EPS) | -$1.62 |
Full Income StatementBalance Sheet
The company has $31.12 million in cash and $20.26 million in debt, giving a net cash position of $10.87 million or $0.41 per share.
| Cash & Cash Equivalents | 31.12M |
| Total Debt | 20.26M |
| Net Cash | 10.87M |
| Net Cash Per Share | $0.41 |
| Equity (Book Value) | 16.94M |
| Book Value Per Share | 0.69 |
| Working Capital | 16.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.36 million and capital expenditures -$424,000, giving a free cash flow of -$25.78 million.
| Operating Cash Flow | -25.36M |
| Capital Expenditures | -424,000 |
| Free Cash Flow | -25.78M |
| FCF Per Share | -$0.97 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |